PT  - JOURNAL ARTICLE
AU  - KENNETH P. BYRD
AU  - NAMRATHA R. VONTELA
AU  - BRENNAN MCCULLAR
AU  - MIKE G. MARTIN
TI  - Multi-Database Description of Primary Splenic Diffuse Large B-Cell Lymphoma
DP  - 2017 Dec 01
TA  - Anticancer Research
PG  - 6839--6843
VI  - 37
IP  - 12
4099  - http://ar.iiarjournals.org/content/37/12/6839.short
4100  - http://ar.iiarjournals.org/content/37/12/6839.full
SO  - Anticancer Res2017 Dec 01; 37
AB  - Background/Aim: Stage I splenic diffuse large B-cell lymphoma (DLBCL) is rare and there are few data to guide management. We sought to further define prognosis and outcomes. Materials and Methods: We utilized the Surveillance, Epidemiology, and End Results registry to identify patients with stage I splenic DLBCL diagnosed 1973-2013. Patients were divided into two cohorts based on the year of diagnosis (1983-2005; 2006-2013) as rituximab was approved by the U.S. Food and Drug Administration in 2006 for first-line treatment of DLBCL. Results: Utilization of splenectomy decreased after the approval of rituximab (82% pre- versus 72% rituximab-era). Disease-specific and overall survival were greater with splenectomy [hazard ratio (HR)=0.57, p=0.04; and HR=0.66, p=0.03, respectively], but this benefit was only seen in the pre-rituximab cohort, not in the rituximab-era cohort. There was a trend toward improved overall survival with the introduction of rituximab (HR=0.75, p=0.054). Conclusion: Utilization of splenectomy for stage I splenic DLBCL has decreased with the introduction of rituximab without compromising outcomes.